Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / 浩博医药AusperBio 医疗创新

浩博医药AusperBio 医疗创新

Series CUScn.ausperbio.com
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
2
Disclosed raised
$183Msum of rounds with a disclosed amount only
Named investors
7
Financing history
2 rounds
  1. Aug 27, 2026
    Series C · $120M (disclosed)
    HanKang Capital (participant)Sherpa Capital (participant)InnoPinnacle Fund (participant)Qiming Venture Partners (participant)YuanBio Venture Capital (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies”
  2. Sep 21, 2025
    Series B2 · $63.0M (disclosed)
    Qiming Venture Partners (lead)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis B”
Investors on record
8 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
2
  1. Aug 27, 2026
    AusperBio announced Series C of $120,000,000
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
  2. Sep 21, 2025
    AusperBio announced Series B2 of $63,000,000, led by Qiming Venture Partners
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
6 observations
Every observation on this company